

OTCQB Certification

I, Deina H. Walsh, Chief Financial Officer of Bone Biologics Corporation ("the Company"), certify that:

a. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC registration as indicated below (check one):

- Company is registered under Section 12(g) of the Exchange Act
- Company is relying on Exchange Act Rule 12g3-2(b)
- Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
- Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
- Company is reporting under Section 15(d) of the Exchange Act.
- Other (describe) _____

b. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC's EDGAR system or the OTC Disclosure & News Service, as applicable.

c. The Company Profile displayed on www.otcmarkets.com is current and complete as of January 11, 2016 and includes the total shares outstanding, authorized, and in the public float as of that date.

d. The following is a complete list of attorney(s) and law firm(s) who advised or assisted in the preparation of the Company's most recent annual report, including in-house counsel: (If no attorney assisted in putting together the disclosure, indicate the person or persons who prepared the disclosure and their relationship to the company.)

Current representation:

TroyGouldPC/David Ficksman
1801 Century Park East, Suite 1600,

Los Angeles, CA 90067

Prior representation:

William N. Haddad, Esq.

Reed Smith LLP

599 Lexington Avenue

New York, NY 10022

e. The following is a complete list of third party providers, including names and addresses, engaged by the Company, its officers, directors or controlling shareholders, during the period from the Company's prior fiscal year end to the date of this OTCQB Certification, to provide investor relations services, public relations services, or other related services to the Company including promotion of the Company or its securities:

None currently engaged

f. Listed below are the names, legal addresses and % of shares owned by all Officers, Directors and Control Persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities). If any of the beneficial shareholders are corporate shareholders, the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders must also be included.

Name	Address (City and State only)	% Shares Owned
The Musculoskeletal Transplant Foundation; Michael Kawas, Control Person	125 MAY STREET SUITE 300, Edison, NJ 08837	35.5%
Hankey Capital LLC; Don R. Hankey, Control Person	4751 WILSHIRE BLVD STE #110, Los Angeles, CA 90010	29.9%
AFH Holding and Advisory LLC;	6363 LUNITA RD, Mailbu, CA 90265	19.0%

Amir Heshmatpour, Control Person		
Stephen R. LaNeve, CEO and Director	106 McCool Blvd, West Chester, PA 19380	0%
Deina H. Walsh, CFO	21835 Tobarra, Mission Viejo, CA 92692	0.5%
Jeffrey Frelick, COO	1 Fox Run Lane, Lexington, MA 02420	0%
Bruce Stroeveer, Chairman	76 Winay Terrace, Long Valley, NJ 07853	0%
Dr. Bessie (Chia) Soo, Director	115 N DOHENY DR, Beverly Hills, CA 90211	9.8%
William Coffin, Director	3966 Deervale Dr., Sherman Oaks, CA 91403	0.3%
Steve Warnecke, Director	1026 Anaconda Dr., Castle Rock, CO 80108	0.3%
Jimmy Deshland, Director	132 S. Maple Drive PH-3, Beverly Hills, CA 90212	0.3%
John Booth, Director	7 Red Pine Rd, North Oaks, MN 55127	0.3%
George Oram, Director	12 Edgemont Lane, Bromister, NJ 07921	0.3%
Dr. Benjamin Wu, Director	2740 LORAIN RD, San Marino, CA 91108	3.0%

Date: 1/12/16

Name of Certifying CEO or CFO: Deina H. Walsh

Title: CFO

Signature: /s/ Deina H. Walsh

(Digital Signatures should appear as "/s/ [OFFICER NAME]")